{"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"groups":[{"description":"Participants received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Participants who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"BG000","title":"Romidepsin"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.83","value":"59.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"89"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.2348","value":"1.84"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"128"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"participants with a Baseline measurement","title":"Body Surface Area (BSA)","unitOfMeasure":"m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"66"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Missing"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Unknown"}],"description":"The ECOG scale is as follows: Grade 0: Fully active, able to carry on all pre-disease activities without restriction; Grade 1: Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; Grade 2: Ambulatory and capable of all self-care but unable to work. Up and about more than 50% of waking hours; Grade 3: Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Confined to bed or Chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.6654","value":"2.268"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Duration of peripheral T-cell lymphoma (PTCL)","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"PTCL Unspecified (NOS)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Angioimmunoblastic T-cell lymphoma (AITL)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"ALK-1 negative ALCL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Enteropathy-type T-cell lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Subcutaneous panniculitis-like T-cell lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"ALK-1 positive ALCL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Cutaneous γδ T-cell lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Extranodal NK/T cell lymphoma nasal type"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Transformed mycosis fungoides"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"131"}],"units":"Participants"}],"title":"Unknown"}],"description":"ALK-1=anaplastic lymphoma kinase; ALCL=anaplastic large cell lymphoma","paramType":"COUNT_OF_PARTICIPANTS","title":"PTCL Subtype Based on Central Diagnosis","unitOfMeasure":"Participants"}]}